ASH 2024: Updates in the Treatment of CLL - Episode 14

Emerging Data on BTK Inhibitor Degraders and Bispecifics in R/R CLL: Updated Results at ASH 2024

February 18, 2025

Panelists discuss how novel Bruton tyrosine kinase (BTK) degraders like NX-5948 and BGB-16673 are showing promising early clinical activity in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) based on ASH 2024 data, while bispecific antibodies such as epcoritamab from the EPCORE CLL-1 trial represent another emerging therapeutic approach, though longer follow-up is needed to fully understand their optimal role in the treatment landscape.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Expert Insights in Selecting Frontline Therapies in TN CLL: Fixed-Duration Venetoclax vs Continuous BTKi

EP. 2: ASH 2024 Updates: SEQUOIA 5-Year Follow-Up and Expert Perspectives in Selecting Between Acalabrutinib vs Zanubrutinib in TN CLL

EP. 3: Real-World Observations: Firstline cBTKi Switches and Cardiac AEs in TN CLL

EP. 4: Clinical Insights: Exploring Combination Regimens in First-Line Treatment in CLL: SEQUOIA Arm D and BOVen Trials

EP. 5: Key Takeaways From the AMPLIFY Trial at ASH 2024: Fixed-Duration Acalabrutinib Plus Venetoclax With or Without Obinutuzumab vs Chemoimmunotherapy in TN CLL

EP. 6: ASH 2024 Updates: Evaluating Potential Frontline Triplet Regimen: Pirtobrutinib Plus Venetoclax Plus Obinutuzumab in TN CLL

EP. 7: Expert Perspectives: Navigating the Emerging Treatment Landscape of Combination Therapies in TN CLL—Applying Evidence to Clinical Practice

EP. 8: Expert Insights: Treatment Selection in Second-Line R/R CLL and Limitations of Applying MAIC Data in the Real-World Practice Setting

EP. 9: ASH 2024 Highlights: Phase 2 Study of Zanubrutinib Plus Venetoclax in R/R CLL

EP. 10: Treatment Sequencing in R/R CLL: Optimizing Strategies and Clinical Insights From ASH 2024 Real-World Data

EP. 11: Pirtobrutinib in R/R CLL: Can It Be Used in the Second-Line Setting?

EP. 12: Sequencing Treatment in R/R CLL: CAR T-Cell Therapy vs Pirtobrutinib in Double-Exposed Patients

EP. 13: Real-World Observations With Pirtobrutinib and New Data From the BRUIN CLL-321 Trial at ASH 2024

Now Viewing

EP. 14: Emerging Data on BTK Inhibitor Degraders and Bispecifics in R/R CLL: Updated Results at ASH 2024

EP. 15: Reflecting on 2024 in CLL: Key Advances and Looking Ahead to 2025

Video content above is prompted by the following:

There’s been a lot of emerging data with the BTK degraders in R/R CLL. Dr Kahl, what are your perspectives/insights on novel agents like NX-5948?
What are your thoughts on agents like BGB-16673?
Another exciting class is bispecifics in R/R CLL. Can you share the updated results with epcoritamab from the EPCORE CLL-1 trial?